Mesoblast Limited (MESO), an allogeneic cellular medicine company, will be showcasing its recently FDA-approved product, Ryoncil or remestemcel-L, at the 2025 Transplantation & Cellular Therapy Tandem Meetings in Honolulu.
Approved in December 2024, Ryoncil is the first mesenchymal stromal cell or MSC therapy approved by the FDA for the treatment of steroid-refractory acute graft-versus-host disease or SR-aGvHD in pediatric patients aged 2 months and older.
SR-aGvHD is a severe and life-threatening complication following stem cell or bone marrow transplants, and Ryoncil is poised to become a critical treatment option for these patients.
At the Tandem meetings, Mesoblast is offering an information hub to support healthcare providers in preparation for Ryoncil's market launch.
The company is also presenting scientific and clinical data supporting the efficacy and safety of Ryoncil, including a key presentation by Mesoblast executives.
Additionally, Dr. Joanne Kurtzberg of Duke University Medical Center is delivering a poster presentation on Ryoncil as a third-line treatment for SR-aGvHD in adolescents and adults.
Ryoncil's approval marks a significant milestone for Mesoblast's allogeneic MSC therapy platform, which is focused on treating severe inflammatory conditions.
The company also continues to develop additional cell therapies for other indications, further advancing its leadership in the field.
Currently, MESO is trading at $17.99, down by 2.20 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.